Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration

Wadhwa, Punit D; Lazarus, Hillard M; Koc, Omer N; Jaroscak, Jennifer; Woo, David; Stevens, Cladd E; Rubinstein, Pablo; Laughlin, Mary J

« Previous Next »Leukemia Research
Volume 27, Issue 3 , Pages 215-220, March 2003

Hematopoietic recovery after unrelated umbilical cord-blood allogeneic transplantation in adults treated with in vivo stem cell factor (R-MetHuSCF) and filgrastim administration

Punit D Wadhwa
- Allogeneic Transplant Program, Case Western Reserve University, Department of Medicine, Ireland Comprehensive Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 433, Cleveland, OH 44106-5065, USA
Hillard M Lazarus
- Allogeneic Transplant Program, Case Western Reserve University, Department of Medicine, Ireland Comprehensive Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 433, Cleveland, OH 44106-5065, USA
Omer N Koc
- Allogeneic Transplant Program, Case Western Reserve University, Department of Medicine, Ireland Comprehensive Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 433, Cleveland, OH 44106-5065, USA
Jennifer Jaroscak
- Department of Paediatrics, University Hospital of Cleveland, Case Western Reserve University, Cleveland, OH 44106-5065, USA
David Woo
- Amgen Inc., Thousand Oaks, CA 91320, USA
Cladd E Stevens
- Placental Blood Program, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Pablo Rubinstein
- Placental Blood Program, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Mary J Laughlin
- Allogeneic Transplant Program, Case Western Reserve University, Department of Medicine, Ireland Comprehensive Cancer Center, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 433, Cleveland, OH 44106-5065, USA
- Corresponding author. Tel.: +1-216-844-4766; fax: +1-216-844-3616.

Received 29 October 2001; accepted 8 May 2002.

Abstract

Transplantation with unrelated umbilical cord blood (UCB) is marked by delayed hematologic recovery. This report summarizes two adults with chronic myelogeneous leukemia (CML), who received myeloablative conditioning followed by infusion of a non-expanded single UCB graft. These CML patients were enrolled in a clinical trial incorporating concomitant in vivo administration of stem cell factor (R-MetHuSCF) and filgrastim from day of UCB infusion until attained hematopoietic recovery. Each patient engrafted fully with donor UCB, with days to absolute neutrophil count (ANC) >500/μl being 13 and 29 days, respectively. Both patients remain in cytogenetic remission at 28 months follow-up. ‘In vivo UCB expansion’ with administration of concomitant R-MetHuSCF and filgrastim may facilitate prompt hematologic engraftment.

Abbreviations: UCB, umbilical cord blood, R-MetHuSCF, recombinant methionyl human stem cell factor, GVHD, graft-versus-host disease

Keywords: Umbilical cord blood, Stem cell factor, Hematopoiesis